Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenue:    
Grant and licensing revenue $ 901,880 $ 701,062
Operating expenses:    
Research and development 2,782,506 3,172,247
General and administrative 3,270,548 3,347,601
Change in fair value of contingent consideration (27,000) 114,290
Total operating expenses 6,026,054 6,634,138
Loss from operations (5,124,174) (5,933,076)
Change in fair value of warrant liability (977,710)  
Investor relations expense (66,767)  
Interest income 52,710 150,852
Other (expense) income, net (257,479) 8,321
Total non-operating income (loss) (1,249,246) 159,173
Net loss before income taxes (6,373,420) (5,773,903)
Income tax (expense) benefit   (45,178)
Net loss (6,373,420) (5,819,081)
Net loss - non-controlling interest (81,314) (103,605)
Net loss attributable to Heat Biologics, Inc. $ (6,292,106) $ (5,715,476)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.11) $ (0.17)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 57,282,075 33,225,164
Comprehensive loss    
Net loss $ (6,373,420) $ (5,819,081)
Unrealized gain (loss) on foreign currency translation 218,804 (8,189)
Total comprehensive loss (6,154,616) (5,827,270)
Comprehensive loss attributable to non-controlling interest (81,314) (103,605)
Comprehensive loss - Heat Biologics, Inc. $ (6,073,302) $ (5,723,665)